Navigation Links
Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
Date:9/25/2007

Conference Call to Be Held Tomorrow, Wednesday, September 26th at 8:30am

NEW YORK, Sept. 25 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX) announced today that it will conduct a conference call to discuss a strategic alliance surrounding one of its Phase II portfolio products for a territory outside the US.

The call will take place tomorrow, Wednesday, September 26, 2007, at 8:30am EDT. Michael S. Weiss, Chairman and CEO of Keryx Biopharmaceuticals will host the call.

Interested parties may participate in the call by dialing 1-877-719-9796 (U.S.), 1-719-325-4777 (outside the U.S.), call-in ID: KERYX. The audio recording of the conference call will be available for replay at http://www.keryx.com, for a period of 15 days after the call.

ABOUT KERYX BIOPHARMACEUTICALS, INC.

Keryx Biopharmaceuticals, Inc. is focused on the acquisition, development and commercialization of medically important, novel pharmaceutical products for the treatment of life-threatening diseases, including diabetes and cancer. Keryx's lead compound under development is Sulonex(TM) (sulodexide), previously referred to as KRX-101, a first-in-class, oral heparinoid compound for the treatment of diabetic nephropathy, a life-threatening kidney disease caused by diabetes. Sulonex is in a pivotal Phase III and Phase IV clinical program under a Special Protocol Assessment with the Food & Drug Administration. Additionally, Keryx is developing Zerenex(TM), an oral, inorganic, iron-based compound that has the capacity to bind phosphate and form non-absorbable complexes. Zerenex is currently in Phase II clinical development for the treatment of hyperphosphatemia (elevated serum phosphorous levels) in patients with end- stage renal disease. Keryx is also developing clinical-stage oncology compounds, including KRX-0401 (perifosine), a novel, first-in-class, oral modulator of Akt, a pathway associated with tumor survival and growth, and other important signal transduction pathways. KRX- 0401 is currently in Phase II clinical development for multiple tumor types. Keryx also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. Keryx is headquartered in New York City.

KERYX CONTACT:

Lauren Fischer

Director - Investor Relations

Keryx Biopharmaceuticals, Inc.

Tel: 212.531.5965


'/>"/>
SOURCE Keryx Biopharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... ... 2017 , ... LabKey and collaborator Just Biotherapeutics, Inc. (Just) ... LabKey Biologics . Built in collaboration with Just and designed with input from ... research teams tools for biological entity registration, assay data integration, and workflow management ...
(Date:3/28/2017)... ... March 28, 2017 , ... ... brand-new, fully-certified hygienic SWB805 MultiMountTM weigh modules. These weigh modules are designed ... by National Sanitation Foundation (NSF). , As fully integrated weighing solutions, SWB805 ...
(Date:3/28/2017)... ... March 28, 2017 , ... Executive search firm, ... Avomeen Analytical Services. Harvill is a distinguished life sciences expert with a proven ... a leader in a wide range of services related to laboratory testing and ...
(Date:3/27/2017)... 2017 Cousins Properties (NYSE: CUZ ) ... companies, has signed a 10-year, approximately 125,000 square-foot lease at ... located in the Westshore submarket of Tampa, FL. ... has chosen Corporate Center for their new location in ... and chief executive officer of Cousins Properties. "Amgen is a ...
Breaking Biology Technology:
(Date:3/27/2017)... 2017  Catholic Health Services (CHS) has been ... (HIMSS) Analytics for achieving Stage 6 on the ... In addition, CHS previously earned a place in ... electronic medical record (EMR). "HIMSS Analytics ... EMR usage in an outpatient setting.  This recognition ...
(Date:3/22/2017)... Lithuania , March 21, 2017   ... and object recognition technologies, today announced the release ... kit (SDK), which provides improved facial recognition using ... cameras on a single computer. The new version ... to improve accuracy, and it utilizes a Graphing ...
(Date:3/16/2017)... CeBIT 2017 - Against identity fraud with DERMALOG solutions "Made in Germany ... ... one project, multi-biometric solutions provide a crucial contribution against identity fraud. (PRNewsFoto/Dermalog Identification Systems) ... Used combined in one project, multi-biometric solutions provide a crucial contribution ... ...
Breaking Biology News(10 mins):